Documentation of Humira in Psoriasis Patients in Routine Clinical Practice

Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00237887 ·Status: COMPLETED ·Phase: PHASE3

Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00646191 ·Status: COMPLETED ·Phase: PHASE2

Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00645905 ·Status: COMPLETED ·Phase: PHASE2

Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet

NCT00735787 ·Status: COMPLETED ·Phase: PHASE4

Extension Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00645892 ·Status: COMPLETED ·Phase: PHASE2

Evaluation of Humira Retention Rate in Psoriasis Patients in Daily Practice and Assessment of Work Productivity and Quality of Life

NCT01169987 ·Status: COMPLETED

Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira

NCT02016105 ·Status: COMPLETED ·Phase: PHASE3

Mechanism of Action Study for Psoriasis

NCT00932113 ·Status: COMPLETED ·Phase: PHASE4

Effectiveness of Adalimumab in Moderate to Severe Plaque Psoriasis Patients With Distinct Co-morbidities

NCT01401452 ·Status: COMPLETED

Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients With Psoriasis Severe or Moderate With Adalimumab Treatment

NCT01316224 ·Status: COMPLETED

A Canadian Open-Label Access Program to Evaluate Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriasis

NCT00513370 ·Status: COMPLETED ·Phase: PHASE3

A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis

NCT05073315 ·Status: COMPLETED ·Phase: PHASE3

Safety and Efficacy of Multiple Doses of BT061 in Patients With Moderate to Severe Chronic Plaque Psoriasis

NCT01072383 ·Status: COMPLETED ·Phase: PHASE2

Immediate Response With Adalimumab and Its Impact on Quality of Life and Other Comorbidity Factors in Patients With Moderate to Severe Plaque Psoriasis

NCT01265823 ·Status: COMPLETED ·Phase: PHASE4

Therapeutic Drug Monitoring of Adalimumab in Psoriasis Patients

NCT02147600 ·Status: COMPLETED

A Study to Provide Real-world Evidence on the Treatment Goal Achievement Rate, Adherence to and Utilization Patterns of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in Greece

NCT02713295 ·Status: COMPLETED

Greek Study of the Quality of Life in Patients With Psoriasis Treated With Adalimumab

NCT01077128 ·Status: COMPLETED

Pharmacokinetics, Efficacy, Safety, and Immunogenicity of SB5 Versus Humira in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT05510063 ·Status: COMPLETED ·Phase: PHASE4

MSB11022 in Moderate to Severe Chronic Plaque Psoriasis

NCT02660580 ·Status: COMPLETED ·Phase: PHASE3

Efficacy, Safety, and Immunogenicity of AVT04 With Moderate-to-Severe Chronic Plaque Psoriasis

NCT04930042 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate ABY-035 in Subjects With Moderate-to-severe Plaque Psoriasis

NCT03591887 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00195676 ·Status: COMPLETED ·Phase: PHASE3

Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00235820 ·Status: COMPLETED ·Phase: PHASE3

Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis

NCT02581345 ·Status: COMPLETED ·Phase: PHASE3

MAP Study: Methotrexate and Adalimumab in Psoriasis

NCT03217734 ·Status: COMPLETED ·Phase: PHASE2/PHASE3